|Publication Type||Journal Article|
|Year of Publication||2008|
|Authors||Hoshida, Y, Villanueva, A, Kobayashi, M, Peix, J, Chiang, DY, Camargo, A, Gupta, S, Moore, J, Wrobel, MJ, Lerner, J, Reich, M, Chan, JA, Glickman, JN, Ikeda, K, Hashimoto, M, Watanabe, G, Daidone, MG, Roayaie, S, Schwartz, M, Thung, S, Salvesen, HB, Gabriel, S, Mazzaferro, V, Bruix, J, Friedman, SL, Kumada, H, Llovet, JM, Golub, TR|
|Journal||The New England journal of medicine|
It is a challenge to identify patients who, after undergoing potentially curative treatment for hepatocellular carcinoma, are at greatest risk for recurrence. Such high-risk patients could receive novel interventional measures. An obstacle to the development of genome-based predictors of outcome in patients with hepatocellular carcinoma has been the lack of a means to carry out genomewide expression profiling of fixed, as opposed to frozen, tissue.